We study the incidence of delayed graft function (DGF) in a group of 3365 renal transplant recipient patients from various Spanish centres, its clinical consequences, and the evolution in time (transplants performed in 1990, 1994 and 1998) of the factors that determine its presence. The incidence of DGF remained constant in the 3 years studied (30.4, 30.8 and 29.2%, respectively) when contrasting the following factors involved in the establishment of DGF were studied: body mass of recipient, donor age, non-heart beating donation, type of replacement treatment in the pre-transplant period, time of vascular anastomosis and time of cold ischaemia. DGF was not associated with graft or patient survival. In the transplants performed with elderly donors, the cold ischaemia time was associated with greater incidence of DGF, and the latter with less survival of the graft when censored for death. The presence of DGF was significantly associated with acute rejection, cytomegalovirus infection, worse renal function and arterial hypertension at 3 months post-transplantation. In conclusion, the incidence of DGF remained stable in our patients over the years studied and, although not directly, it can affect graft survival as it is associated with acute rejection, arterial hypertension and worse renal graft function. A shortening of ischaemia times may reduce the incidence of DGF and improve transplant results.
Background
The delay in the beginning of function of the graft [delayed graft function (DGF)] forms part of the natural history of the immediate post-renal transplant period. In the absence of other complications, it was initially attributed to acute tubular necrosis secondary to the ischaemic lesions involved in the actual transplant process. Other factors that participate in its establishment have subsequently been discovered. Therefore, it is now preferred to talk about DGF, a concept that covers all causes [1] .
Prolonged periods of cold and warm ischaemia, greater age of the donor, brain death of the donor, haemodynamic instability of the cadaveric donor prior to kidney removal, greater body mass of recipient, the use of nephrotoxic drugs, etc., are all recognized factors that cause DGF [1, 2] .
The clinical importance of DGF is clear. In the short term it hinders transplant patient management, facilitates infectious processes, requires the practice of dialysis, and can favour and conceal acute rejection [2] . In the long term, it can lead by itself or through immunological mechanisms to chronic nephropathy of the transplant, which is currently, together with death of the patient, the greatest cause of graft loss after the first year of transplantation [3] . It is therefore of interest to recognize the factors that trigger it, to attempt to reduce its incidence and thus improve the short-and long-term function and survival of graft and patient.
This study analyses how the factors related to DGF and its clinical consequences are expressed over time (year of transplantation 1990, 1994 and 1998) in a group of 3365 patient transplanted in various Spanish transplantation centres, with an aim to try to modify strategies which could trigger an improvement in the current outcomes of renal transplantation.
Subjects and methods
DGF was defined as dialysis requirements during the first week after transplantation once urinary tract obstruction, vascular complications and acute rejection were ruled out.
The assessment of risk factors for DGF was conducted by means of a multiple logistic regression model. This model was also used to estimate the expected increase in the fraction of patients with DGF due to changes in positive and negative risk factors between years of transplantation. These results were extracted, evaluating the positive risk factors values in 1990 and in 1998 (fixing the negative risk factors values), obtaining the change in percentage of patients with delayed graft function (for positive risk factors). The same was made for negative risk factors. Table 1 describes how potential risk factors for DGF differed significantly between years of transplantation, although the incidence of DGF remained stable. However, some of these factors like recipient age, last panel reactive antibodies and number of HLA mismatches were not found to significantly predict presence or absence of DGF. As shown in Table 2 , factors favouring the presence of DGF (positive risk factors) were increased body mass index in 1998 as compared with 1990, increased donor age, and the use of non-heart beating donors. Factors favouring the absence of DGF (negative risk factors) were a higher percentage of peritoneal dialysis (PD) as type of dialysis, lower HCV incidence, reduced cold ischaemia and reanastomosis time, and less frequent addition of antibodies to the immunosuppressive regimen.
Results
Regarding the type of dialysis, the incidence of DGF was lower in patients on PD than for those with haemodialysis (HD). However, this difference was not significant for patients transplanted in 1998 (22.5 vs 29.7%), while it was significant for those transplanted in 1990 (8.6 vs 27.7%) and 1994 (11.1 vs 27.0%). Therefore, although there were more patients on PD in 1998 than in 1990, this factor had no longer a significant effect on DGF in 1999.
Regarding the other risk factors, it was found that the effect of positive risk factors cancelled the effect of the negative ones. Adjusted estimate of DGF incidence in 1990 was 27.05%; if only positive risk factors had changed from 1990 to 1998, the incidence would have increased to 28.48%. On the other hand, had changes only been observed in the negative risk factors, the percentage of DGF would have decreased to 23.39% (3.66% decrease).
Increased cold ischaemia time was found to be a risk factor for DGF especially in elderly donors (age >60 years). Also, acute rejection incidence (29.5 vs 40.1%, P<0.0001) and cytomegalovirus infection (24.8 vs 28.3%, P ¼ 0.0545) were significantly higher in patients with DGF. Table 3 describes creatinine, proteinuria and triglycerides for patients with and without DGF, and indicates the prevalence of hypertension during the first year of post-transplantation. As can be seen, renal function at 3 months and 1 year was significantly better among the patients without DGF, although no significant differences were observed in the change in creatinine and proteinuria between 3 months and 1 year, or in the 3 month triglyceride levels. In bivariate analysis, the prevalence of hypertension was significantly higher, although it was not significant in the multivariate study performed by Campistol et al. (in this supplement). No significant differences were observed in the prevalence of statin treatments.
As found by Sero´n et al. (in this supplement), the DGF did not influence patient and graft survival. Only in elderly donors (age >60 years) was the presence of DGF associated with a significantly lower graft survival, without differences in patient survival (Figures 1 and 2 ). The influence of delayed graft function iii33 Chi-square test.
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Discussion
The incidence of DGF after renal transplantation is important and is above 20% in those performed with a kidney from a cadaveric donor [4, 5] . Different studies [3, [6] [7] [8] [9] [10] have related various clinical factors to DGF, such as a background of arterial hypertension in the donor, the duration of the period of time from diagnosis of brain death to organ removal, greater donor and recipient age, cold ischaemia time, transportation of the graft to the implantation centre, double initial immunosuppressive regimens with high doses of prednisone and anticalcineurinic drugs, high body mass of the recipient in relation to that of the donor, average pre-transplant blood pressure of the recipient lower than 100 mmHg and peak panel reactive antibodies of more than 50%. Recently, Peter et al. [11] found a genetic substrate that would grant certain donors resistance to lesions of the ischaemia-reperfusion of the graft. Using polymerase chain reaction, they determined the protective morphism of the glutathione-S-transferase and manganese superoxide dismutase enzymes. In our study, we observed that the incidence of DGF remained constant over the years studied, and that the evolution of these potential risk factors involved in DGF has varied significantly over time. Factors favouring DGF, such as donor age, the number of nonheart beating donors, recipient age, the recipient body mass index, the percentage of panel reactivity antibodies and the number of HLA incompatibilities between donor and recipient have increased considerably. In contrast, cold ischaemia time, warm ischaemia time or secondary ischaemia related to the time of vascular anastomosis have decreased and the use of PD in uraemic patients has increased. All these factors are protective against DGF.
However, we could only establish a significant relationship between DGF and greater body mass of the recipient, greater donor age, non-heart beating donor, HD as replacement treatment in the pretransplant period, prolonged vascular reanastomosis and cold ischaemia times.
Cold ischaemia has been shown to be especially damaging when the transplantation is performed with a kidney from an elderly donor: DGF appears in over 40% of transplant patients when its cold ischaemia is over 24 h. On the other hand, we do not know the physiopathological mechanism that could explain the relationship between the type of dialysis followed by the uraemic patient and DGF. It is possible that a bias occurs in the choice of the patients to follow a certain dialytic regimen, which in turn determines the subsequent development of DGF. We were unable to verify the influence of the treatment with anticalcineurinic drugs on DGF, as most patients were treated with them. A study of the possible benefit of applying immunosuppressive induction regimens free from anticalcineurinic drugs is thus pending. As for the association between the use of antilymphocyte serum and DGF, we believe that it is not causal, but rather that this medication is indicated in many transplant groups, precisely in the patients that present DGF, in allowing the subsequent reintroduction of anticalcineurinic drugs.
The effect of the presence of DGF on patient and graft evolution has not yet been clearly established. For some authors [12] , the immunological factors, such as acute rejection, are the only ones that can determine the presence of a subsequent chronic rejection. For others [7, 9] , DGF itself would have a negative effect on graft evolution. Indeed, in some studies [13] a greater amount of early lesions of a chronic nature have been described in the grafts of patients presenting DGF, which subsequently may lead to chronic nephropathy of the transplant. Kreis and Ponticelli [14] describe DGF as a cause of chronic nephropathy of the immuno-independent transplant, which would cause a reduction in the number of functioning nephrons and a subsequent glomerular hyperfiltration. Thus, Nankivell et al. [13] observe that DGF provides a worse renal function of the graft, which in turn is the origin of its worse prognosis. On the other hand, Ponticelli et al.
[15] observe a worse survival of the grafts of patients who have suffered from DGF, although they were not able to identify whether only the grafts with kidney failure are lost. On the other hand, Shoskes et al. [16] believe that DGF triggers immunological mechanisms responsible for long-term graft damage. Other studies [17] , however, only see graft survival negatively affected in patients with DGF in the first year posttransplantation. Other authors only observe worse graft survival when acute rejection is added to DGF [16, 17] . These combined lesions represent a cause of graft loss, which does not occur when only DGF is established without an additional rejection. Qureshi et al. [18] only attribute a secondary role to DGF: its establishment worsens graft survival by concealing the presence of different silent clinical acute rejection crises. Finally, other authors observe the negative aspect of DGF for graft survival, mainly when the graft comes from an elderly donor [7] . In our group of patients, the presence of DGF in itself only negatively influenced graft survival, after censoring for death, when the kidney came from an elderly donor. However, considering any kind of donor, we were able to relate DGF to acute rejection and kidney dysfunction, which did demonstrate their negative influence on patient and graft survival. Thus, like the majority of authors, we detected a greater incidence of acute rejection in the patients that presented with DGF. The mechanism by which DGF and acute rejection are associated has not been completely clarified, but a greater expression of MHC is invoked in the kidneys that suffered from a period of ischaemia, which would more easily provoke the immunological response of the recipient [7, 16, 19] .
DGF has also been shown to be an independent risk factor for suffering from cytomegalovirus infection and arterial hypertension. The persistence of the uraemic state after the transplantation due to DGF, and the higher number of acute rejection crises probably provoke an alteration of the recipient's immunity, making them more vulnerable to infectious agents. The fact that the patients with DGF receive a larger quantity of treatment with antilymphocyte serum does not appear to increase the presence of cytomegalovirus after transplantation [20] .
The greater incidence of arterial hypertension in the first 3 months after transplantation may be due to the worse renal function of these patients and to the higher doses of steroids administered because of a higher number of acute rejection crises [10] .
In conclusion, the incidence of DGF has remained stable over time in this series of transplanted patients, given the equivalent variation in more or in less of the protective or favouring factors, respectively. DGF, which is not shown to be an independent risk factor for patient or graft survival, except in the case of an elderly donor, is significantly associated with acute rejection and with worse renal function, compromising the general results of transplantation. DGF is also related to a greater incidence of cytomegalovirus infections and arterial hypertension in the immediate post-transplantation period.
The positive variation of the modifiable factors that produce DGF, such as a shortening of ischaemia times, can reduce its incidence, thus contributing to an improvement in renal transplantation results.
